Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDK12 dec exp |
Therapy | Cisplatin |
Indication/Tumor Type | ovarian cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDK12 dec exp | ovarian cancer | sensitive | Cisplatin | Preclinical | Actionable | In a preclinical study, the depletion of CDK12 in an ovarian cancer cell line by siRNAs resulted in the depletion of BRCA1 and sensitized the cells to the cross-linking agents Alkeran (melphalan), Platinol (cisplatin), and the PARP inhibitor veliparib (ABT-888) (PMID: 24554720). | 24554720 |
PubMed Id | Reference Title | Details |
---|---|---|
(24554720) | Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. | Full reference... |